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Available online 29 April 2014Abstract The history of revascularization for cardiac ischemia dates back to the early 1960’s when the first coronary artery
bypass graft procedures were performed in humans. With this 50 year history of providing a new vasculature to ischemic
and hibernating myocardium, a profound depth of experience has been amassed in clinical cardiovascular medicine as to
what does, and does not work in the context of cardiac revascularization, alleviating ischemia and adequacy of myocardial
perfusion. These issues are of central relevance to contemporary cell-based cardiac regenerative approaches. While the
cardiovascular cell therapy field is surging forward on many exciting fronts, several well accepted clinical axioms related to the
cardiac arterial supply appear to be almost overlooked by some of our current basic conceptual and experimental cell therapy
paradigms. We present here information drawn from five decades of the clinical revascularization experience, review relevant
new data on vascular formation via cell therapy, and put forward the case that for optimal cell-based cardiac regeneration due
attention must be paid to providing an adequate vascular supply.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 667
Heart failure, hibernating myocardium and the importance of an adequate perfusing vasculature . . . . . . . . . . . . 667
Heart failurex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 667
Hybernating myocardium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668
Burden of ischemia and complete revascularization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669
Endothelial cells may orchestrate tissue repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670
Insights from inter-strain differences in the murine response to ischemia . . . . . . . . . . . . . . . . . . . . . . 671
Human arteriogensis and angiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672⁎ Corresponding author at: Mount Sinai Hospital, One Gustave L. Levy Place, Box 1030, New York, NY 10029. Fax: +1 212 534 2845.
E-mail address: jason.kovacic@mountsinai.org (J.C. Kovacic).
http://dx.doi.org/10.1016/j.scr.2014.04.009
1873-5061/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
667The cardiac stem cell compartmentCell therapy and new vessel formation – what have we learned so far? . . . . . . . . . . . . . . . . . . . . . . . . . 672
Early cell-therapy studies – bone marrow-derived and circulating progenitor cells . . . . . . . . . . . . . . 673
Contemporary studies of bone marrow-derived cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 673
The existence of a bipotent hemangioblast? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 674
Can resident adult cardiac stem cells form physiologically significant new vessels? . . . . . . . . . . . . . . 675
Epicardial-derived cells and vessel formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 676
Skeletal myoblast therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678
Cardiac development, embryonic and induced pluripotent stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . 678
Developmental origins of the coronary vasculature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678
Perspectives on current reprogramming and differentiation approaches . . . . . . . . . . . . . . . . . 678
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679Introduction
Cardiovascular regenerative medicine can be arbitrarily
divided into a number of sub-disciplines or fundamentally
different approaches based on the underlying principle that
is being utilized to regenerate cardiovascular tissue. While
there is considerable overlap, each sub-discipline has
evolved somewhat independently and often calls upon
a specific additional field of research that is brought to
the fore for the purpose of cardiovascular regeneration.
Examples would include angiogenic approaches that aim to
augment new vessel formation and which draw upon the
fields of vascular medicine and hematology (e.g. endothelial
progenitor cell-based therapies); myogenic approaches that
aim to form new cardiac muscle (e.g. myoblast therapy or
direct fibroblast reprogramming to a cardiomyocyte fate via
defined factors); or more process-driven approaches such as
bone marrow cell therapy, targeted epicardial stimulation
(e.g. by thymosin β4) or attempts to harness/recapitulate
dedifferentiation of somatic cells toward a stem cell state.
Among these approaches, the great majority are geared
toward producing new cardiomyocytes, with angiogenic
approaches being notably less common. Indeed, in most
situations where cell-based regenerative approaches have
attempted to generate cardiomyocytes, the need for an
adequate perfusing vasculature is often neglected or, at
best, an afterthought. This may be an important oversight in
our thinking, as the most prevalent cause of congestive
heart failure (CHF) is myocardial ischemia due to occlusive
atherosclerotic coronary artery disease (CAD). Indeed, it
would appear somewhat naive to presume that any cell-
based regenerative therapy will perform optimally in the
setting of occluded epicardial coronary arteries, or that a
therapy that is directed toward generating new cardio-
myocytes will serendipitously also produce adequate new
vessels. While investigators have been aware of these
concerns, given the nascent nature of the field there was
previously little attention paid to these aspects. With the
recent impressive strides that have been made in cardiovas-
cular regenerative medicine (many of which are reviewed in
this issue of Stem Cell Research) we believe it is timely and
appropriate to now also focus on the “vascular realities” of
achieving heart regeneration and rejuvenation in contem-
porary patients.Heart failure, hibernating myocardium and the
importance of an adequate perfusing vasculature
Heart failurex
Readers will be aware that one of the major focuses of
cardiovascular cell-therapy to date has been to improve
cardiac contractility in patients with reduced left ventricu-
lar ejection fraction and CHF. Importantly, the most
common cause of CHF and left ventricular systolic dysfunc-
tion is occlusive atherosclerotic disease of the epicardial
coronary arteries (Hunt et al., 2009; Lloyd-Jones et al.,
2002). By pooling data from 24 multi-center trials studying
CHF in over 43,000 patients, it has been estimated that CAD
is responsible for CHF in over 60% of patients (Gheorghiade
et al., 2006). Furthermore, CHF patients with CAD have a
worse prognosis than patients with non-ischemic cardiomy-
opathy, with the extent of CAD inversely related to survival
(Bart et al., 1997; Felker et al., 2002). In addition, there is
substantial evidence that atherosclerotic lesions progress
over time in a predictable fashion. Both retrospective and
prospective studies have shown that initially mild plaques on
angiography can become severe over 1–3 years and lead to
acute coronary events including death from cardiac causes,
cardiac arrest, myocardial infarction (MI), or rehospitaliza-
tion due to unstable or progressive angina (Stone et al.,
2011; Ambrose et al., 1988; Glaser et al., 2005).
Patients with established CHF also are at high risk for
suffering adverse outcomes due to further ischemic insults.
For example, Uretsky et al found that in CHF patients with
CAD who die suddenly, over 55% have evidence of an acute
coronary event at autopsy (Uretsky et al., 2000). Addition-
ally, the most common structural abnormalities leading to
sudden cardiac death are features of CAD, including plaque
rupture, thrombosis, or infarct (Davies, 1992).
We believe it is of importance that any cell-based
strategy for CHF and impaired left ventricular contraction
should be designed with an understanding that CAD is the
most common underlying cause, and that atherosclerosis is a
dynamic process that will likely lead to worsening cardiac
ischemia over time. Moreover, any therapy which targets
regeneration of (injured) myocardium without in some way
repairing the coronary vasculature is incomplete, in that it
does not address the primary problem.
Figure 1 Hybernating versus normally perfused cardiomyoctes. (Left) Electron microscopy of normally perfused and functioning
cardiomyocytes, with abundant sarcomeres (sm) and mitochondria (m) in the cytoplasm. (Right) Electron microscopy of hibernating
cardiomyocytes is notable for disordered structure, with sarcomeres (sm) seen only at the cell periphery. Glycogen (gl) accumulation
is present in the cytosol and only small mitochondria are present (arrow). Reproduced with permission from Maes et al. (1994).
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The condition of hibernating myocardium is especially
illustrative of what we believe would be likely to occur if
cardiac tissue were successfully regenerated in the absence
of an adequate blood supply. Hibernating myocardium is a
well-defined clinical condition that arises when persistently
impaired myocardial blood flow and ischemia result in
dysfunctional (but viable) cardiac tissue with reduced
cellular metabolic activity and impaired left ventricular
contractility (Rahimtoola, 1985, 1989; Fallavollita et al.,
2003). A similar but less severe condition is “stunned
myocardium,” where perfusion returns to normal at rest,
although there is persistent myocardial dysfunction. Espe-
cially in the case of hibernating myocardium, restoring
normal blood flow is critical since cardiomyocytes can regain
function after revascularization (Vanoverschelde et al.,
2000; Kalra and Zoghbi, 2002). However, cardiomyocytes
cannot survive indefinitely in this “hibernating” state, and
myocyte apoptosis is an ongoing process that appears to
begin as soon as hypoperfusion occurs (Chen et al., 1997).
Hibernating myocardium is characterized by a number
of adaptations at the cellular and molecular level, which
include alterations in cell morphology, apoptosis, and
protein expression. Microscopic analysis of hibernating
myocardium in both human and animal models reveals
dedifferentiated cells with loss of myofilaments and accu-
mulation of glycogen (Fig. 1) (Maes et al., 1994; Bito et al.,
2007). In a swine model, apoptosis of myocytes was seen to
occur in combination with cellular dedifferentiation, leading
to hypertrophy of the remaining functional cardiomyocytes
(Lim et al., 1999). Based on large animal models and human
studies, hibernating myocardium is understood to activatea cell survival program that entails upregulation of genes
and proteins involved in anti-apoptosis, growth, and cyto-
protection (Depre et al., 2004), such as inhibitor of apoptosis
(IAP), vascular endothelial growth factor (VEGF), H11
kinase, heat shock protein 70 (HSP70), hypoxia inducible
factor-1α (HIF-1α), and glucose transporter 1 (GLUT1)
(Fig. 2). Mitochondria also adopt a protective phenotype,
with depressed oxygen utilization mediated by downregula-
tion of key proteins involved in the electron transport
chain (Page et al., 2008; Kelly et al., 2011). Hibernating
cardiomyocytes also have reduced expression of Ca2+-
handling proteins, such as sarcoplasmic reticulum Ca2+-
ATPase (SERCA) and phospholamban, decreased levels of
cAMP (3′-5′cyclic adenosine monophosphate), and increased
expression of the negatively inotropic cytokines tumor
necrosis factor-α and nitric oxide synthase-2 (Fallavollita
et al., 1999; Kalra et al., 2002; Luss et al., 2002). Myocardial
biopsies from patients with reversible LV dysfunction
also demonstrate an increase in α-adrenergic receptor
density and a decrease in β-adrenergic receptor density
(Shan et al., 2000). Overall, these changes provide a likely
explanation for the reduced contractility seen in hibernating
myocardium. In an effort to further elucidate the mecha-
nisms underlying decreased contractility, Bito et al simulat-
ed excitation-contraction coupling in a porcine model of
hibernating myocardium (Bito et al., 2004, 2005). They
found that hibernating cardiomyocytes have a prolonged
action potential, decreased L-type Ca2+ current, and
reduced Ca2+ transient, which is the cytosolic surge in Ca2+
that typically triggers myocardial contraction.
In patients with chronic CAD and resultant hibernating
myocardium, revascularization has been shown to signifi-
cantly improve cardiac performance and clinical outcomes
669The cardiac stem cell compartmentcompared to medical treatment alone (Allman et al., 2002).
Specifically, revascularization can promote reverse remod-
eling and halt progression of ventricular scar (Senior et al.,
2001; Pirolo et al., 1986). Importantly and likely related
to ongoing cardiomyocyte apoptosis (Chen et al., 1997),
growing evidence suggests that early rather than delayed
revascularization is associated with a further survival
benefit (Ling et al., 2013; Bax et al., 2003; Beanlands et
al., 1998). The benefit of revascularization is also notable in
patients with severe CAD. In a subset of patients with CHF
and 3-vessel disease in the Coronary Artery Surgery Study
(CASS), the rate of sudden cardiac death was over 3 times
higher in the medically treated group versus patients who
were surgically revascularized (Holmes et al., 1986).
Collectively, this clinical data should guide translational
research, as it indicates that any innovative therapy for
cardiomyocyte (re)generation must be coupled with adequate
arterial vascularization for optimal results. This applies not only
to attempts at cardiomyocyte regeneration in patients with
CAD, but also to patients with non-ischemic cardiac disease. It is
a simple extrapolation of the above experience with hibernat-
ing myocardium to appreciate that the creation of new
myocardial cells that do not have an adequate vascular supply
will be an ultimately futile clinical exercise. As a further
corollary with respect tomyocardial hibernation, it is important
to note that in many of the potential patient groups that are
being considered for cell-based regenerative therapies, and
especially those with CAD and obstructive arterial lesions, the
provision of adequate arterial vascularization alonewould likelyβ-adrenergic 
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Figure 2 Altered signaling pathways in hibernating myocardium.
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formation, irrespective of any new cardiomyocytes.Burden of ischemia and complete revascularization
Another clinical scenario that is important to consider in the
context of cell-based regenerative therapies is that of the
overall burden of myocardial ischemia and “complete”
versus “incomplete” revascularization. At present, in con-
sidering the clinical treatment of a patient with significant
CAD, clinicians employ what is called the SYNTAX score
to guide their plan for revascularization (i.e. bypass graft
surgery or angioplasty with stenting) (Kovacic et al., 2013).
The SYNTAX score is calculated for each patient based on the
location, complexity, and characteristics of their coronary
atherosclerotic lesions (Sianos et al., 2005). As highlighted
by Head et al, one of the principal aspects of the SYNTAX
score is that it estimates the extent of ischemic myocardium
(Head et al., 2014). Our group has shown, as have many
others, that with an increasing number of lesions and their
complexity, greater SYNTAX scores are related to worse
clinical outcomes including MI and death (Kovacic et al.,
2013). In other words, clinical outcomes are related to the
complexity and burden of CAD (as classified by the SYNTAX
score) and the extent of myocardial ischemia.
This tenet is further supported by clinical trials that
investigated outcomes following “complete” over “incom-
plete” revascularization. In this situation, CAD patientsGLUT1
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Figure 3 Mortality following complete versus incomplete revascularization. Pooled analysis of clinical studies involving 89,883
patients, investigating mortality following coronary revascularization for those deemed to have had complete revascularization (CR)
versus incomplete revascularization (IR) by either coronary artery bypass graft surgery or percutaneous coronary intervention
(angioplasty and stenting). Presented here is the risk ratio and 95% confidence interval (CI) for occurrence of total mortality. Boxes
are the relative risk estimates from each study; the horizontal bars are 95% CIs. The size of the box is proportional to the weight of
the study in the pooled analysis. ACUITY = Acute Catheterization and Urgent Intervention Triage Strategy; ARTS = Arterial
Revascularization Therapies Study; BARI = Bypass Angioplasty Revascularization Investigation; CABG = coronary artery bypass graft;
CABRI = Coronary Angioplasty Versus Bypass Revascularization Investigation; MASS II = Second Medicine, Angioplasty or Surgery
Study; NHLBI = National Heart, Lung, and Blood Institute; RR = risk ratio(s); SYNTAX = Synergy Between PCI With Taxus and Cardiac
Surgery. Reproduced from Garcia et al., 2013, with permission from Elsevier.
670 K.C. Michelis et al.are classified as having had “complete” revascularization
if a blood supply was restored to each of the 3 epicardial
coronary vessels and their major branches. This restora-
tion of blood supply may be achieved either by opening of
obstructive epicardial coronary artery lesions by angio-
plasty with stenting, or by bypassing these lesions with
coronary artery bypass graft surgery. Germane to cell
therapy approaches, it does not include forming capil-
laries, small arterioles or collateral vessels, which are
typically only sufficient to support a hibernating state in
the adult human, but which fail to provide normal arterial
perfusion. On the other hand, “incomplete” revasculari-
zation is deemed to have occurred if major vessels or their
branches remain non-revascularized after bypass surgery
or angioplasty with stenting. In a meta-analysis of nearly
90,000 patients, complete revascularization was associat-
ed with reduced long-term mortality, MI and repeat
coronary revascularization (Fig. 3) (Garcia et al., 2013).
This mortality benefit was also consistent regardless of the
method of revascularization (bypass or stenting). Similar-
ly, a recent randomized controlled trial showed that in
patients with acute MI undergoing infarct-artery percuta-
neous coronary intervention, concurrent additional inter-
vention on non-infarct coronary arteries that were
significantly diseased lead to a reduction in death from
cardiac causes, nonfatal MI, and refractory angina (Wald
et al., 2013). Therefore, on the basis of these dataindicating superiority of complete revascularization, it is
possible to make the argument that novel therapeutic
modalities should be designed with the intention of
regenerating or supplanting all occluded or severely
stenosed coronary vessels, whether or not they are
responsible for myocardial impairment. In any case, it is
clear that the provision of “complete” and adequate
myocardial perfusion has been demonstrated as critically
important across a broad spectrum of patients and
differing clinical scenarios. We suggest that any
cell-based therapy will be likely to eventually fail if it
ignores these well documented clinical facts.Endothelial cells may orchestrate tissue repair
While on its own the above clinical experience regarding the
importance of large conduit coronary vessels is compelling, a
growing body of evidence has indicated that local organ-
specific vessels may play additional ‘angiocrine’ roles which
are necessary for optimal tissue and organ regeneration. The
origins of this concept that ‘angiocrine’ signaling regulates
tissue and organ regeneration lie in developmental studies,
which over several decades have shown extensive cross-
communication between various embryonic cell popula-
tions that is required for correct organ specification. More
recently, studies emerged that specifically indicated the
671The cardiac stem cell compartmentangiocrine role played by endothelial cells during deve-
lopment, with endothelial-endoderm interactions being of
importance for the induction of endocrine pancreatic
differentiation (Lammert et al., 2001) and early hepatic
morphogenesis (Matsumoto et al., 2001). This latter finding
was subsequently confirmed by Takebe et al. (2013), who
demonstrated using induced pluripotent stem cells that
immature endodermal cells destined to track to a hepatic
cell fate could self-organize into three-dimensional liver
buds by recapitulating endothelial-mesenchymal develop-
mental interactions.
In the heart, Shiojima et al. (2005) utilized an elegant
transgenic murine model in which cardiac-specific Akt1
expression promoted physiological hypertrophy in the
short-term, but pathological hypertrophy and cardiomyop-
athy with longer term transgene induction. Supporting the
concept of vascular-cardiac paracrine cross-talk, coronary
angiogenesis was enhanced in the initial phase of physio-
logic cardiac hypertrophy but impaired in the chronic
phase, which was directly related to the ensuing contrac-
tile dysfunction. While potential angiocrine mediators
emanating from the vasculature were not identified, it
was shown that Akt1 signaling induced mammalian target of
rapamycin (mTOR)-dependent production of VEGF and
Angiopoietin (Ang)-2 by cardiomyocytes, which was respon-
sible for coronary angiogenesis during initial physiologic
cardiac hypertrophy (Shiojima et al., 2005). Central to
the theme of this review, these data support our broader
contention that cardiac function is ultimately dictated by
the relative balance between cardiac and coronary vascu-
lature growth, rather than cardiac growth or regeneration
alone.
Building on these studies, the Rafii laboratory has
published several studies which confirm the importance of
vascular-tissue paracrine cross-talk. First in the liver, this
group showed that vascular endothelial growth factor
receptor (VEGFR)-2-expressing hepatic sinusoidal endo-
thelial cells provide angiocrine cues that initiate and sustain
liver regeneration induced by partial hepatectomy (Ding et
al., 2010). Key downstream signaling factors from hepatic
endothelial cells included Wnt2 and hepatocyte growth
factor (HGF), with ablation of this endothelial-derived
angiocrine signaling attenuating liver regeneration. Subse-
quently, the same team showed that divergent angiocrine
signals from hepatic sinusoidal endothelial cells, regulated
by the balance between CXCR7 and CXCR4 signaling,
stimulate either regeneration after immediate injury or
fibrosis after chronic insult (Ding et al., 2014). Moving
to other organs, Raffi and colleagues also demonstrated a
similar phenomenon in the lung, with resection of one
lung triggering activation of VEGFR-2 and fibroblast growth
factor (FGF) receptor 1 in pulmonary capillary endothelial
cells, leading to the production of angiocrine growth factors
including matrix metalloproteinase (MMP) 14. In turn, this
endothelial-derived angiocrine signaling led to epithelial
progenitor cell proliferation and alveologenesis (Ding et al.,
2011). Again, ablation of this endothelial-derived angiocrine
signaling resulted in attenuated lung regeneration.
While at the present time many unanswered questions
remain about endothelial and vascular angiocrine signaling
and the importance of this program in the heart, these
data represent additional and provocative support to ourargument for due attention to the vasculature in cardiac
regenerative strategies.
Insights from inter-strain differences in the
murine response to ischemia
Much attention has recently been paid to the realization that
among differing mouse strains, an identical vascular injury
or stimulus elicits a strain-specific response that varies
significantly in the extent of ischemia, new vessel formation
and vascular remodeling. These differences are prominent
between C57BL/6 and BALB/c mice, with C57BL/6 mice
noted to develop greater neointimal hyperplasia (i.e.
occlusive vascular remodeling – a detrimental outcome),
but also improved recovery after ischemic insults with
increased collateral vasculature (de Vries et al., 2013;
Helisch et al., 2006). While intrinsic differences in resident
or circulating vascular progenitor cells have not been
thoroughly explored, much of this appears attributable
to the pre-existing extent of interarterial connections and
collateral vessels, and strain-specific immune functionality.
With respect to immune function, in broad terms it
appears that C57BL/6 mice have a more activated immune
system that is biased toward a pro-inflammatory response
(de Vries et al., 2013; Schulte et al., 2008). For example, the
biology of Natural Killer (NK) cells differs significantly
between mouse strains. This is at least partly due to
differences in the NK gene Complex (NKC) that encodes
multiple NK cell-related receptors including the polymorphic
Ly49 receptor family. Compared to C57BL/6 mice, BALB/c
mice lack a 200 kb region encoding numerous members of
the Ly49 receptor family. As a result, while C57BL/6 mice
possess 15 Ly49 genes, BALB/c mice have only 8 Ly49 genes
(Proteau et al., 2004; Higuchi et al., 2010). In turn, in a
series of NK cell depletion experiments it was shown that NK
cells in C57BL/6 mice promote vascular remodeling via
Interferon (IFN)-γ leading to increased intimal hyperplasia
compared to BALB/c mice (de Vries et al., 2013). While
numerous other differences in immune function have been
noted among various mouse strains, other aspects that may
be of relevance to vascular formation and remodeling
include a bias toward Th1-type immune response in C57BL/
6 mice, with BALB/c tending to exhibit a Th2-type response
(Schulte et al., 2008).
The extent of pre-existing microvascular connections and
collateral vessels is also of importance for determining the
response following an ischemic insult. Helisch et al. (2006)
were among the first to show that hindlimb interarterial
connections of C57BL/6 mice, compared to BALB/c, are
better able to be recruited, and help to re-establish
perfusion following femoral artery occlusion. Other investi-
gators have shown that there are 35% fewer collateral
vessels in the thigh of BALB/c mice, and correspondingly this
strain has inferior recovery from hindlimb ischemia with 54%
less collateral remodeling, increased ischemia and reduced
angiogenesis compared to C57BL/6 (Chalothorn et al.,
2007). Studies have since demonstrated that these differ-
ences are not limited to the hindlimb, but likely involve most
tissue beds in the body (Chalothorn et al., 2007). Related to
this, there are significant inter-species differences in the
local tissue or skeletal muscle expression of a range of
672 K.C. Michelis et al.angiogenic and other factors, including VEGF, VEGFR-2
(Chalothorn et al., 2007), Ang-2, Tie1, chloride intracellular
channel 4 and other genes/proteins. This may partially
account for baseline differences in collaterals and inter-
arterial connections, but the differing expression of these
factors may also favorably regulate any local angiogenic
response that arises after an ischemic insult in C57BL/6
mice (Chalothorn et al., 2007, 2009; Chalothorn and Faber,
2010; Chen et al., 2010; Wang et al., 2010; McClung et al.,
2012).
The net result of these strain-specific differences is that
while C57BL/6 mice achieve almost full relative perfusion
recovery in the thigh at 14 days after femoral artery
ligation, BALB/c mice experience severe hindlimb ischemia
which may culminate in limb loss. Even at 28 days after
femoral ligation, only about a 40% restoration of hindlimb
perfusion toward baseline levels is observed in BALB/c mice
(Helisch et al., 2006).
These findings offer major insights with respect to
achieving new vessel formation in the context of cardio-
myocyte and cardiac regeneration. Perhaps foremost is the
fact that the recruitment, remodeling and arterialization
(including smooth muscle cell investment) of pre-existing
capillaries and microvascular connections (arteriogenesis)
is the predominant mechanism whereby perfusion is either
partially (BALB/c) or fully (C57BL/6) restored following
injury (Helisch et al., 2006; Chalothorn et al., 2007, 2009;
Chalothorn and Faber, 2010; Wang et al., 2010;
Mac Gabhann and Peirce, 2010). The corollary of this is
that the de novo formation of new vessels, sometimes
referred to as adult vasculogenesis, either does not occur or
plays a minor role in the typical injury response (Kovacic et
al., 2008a). While it may be possible that with specific
stimulation or therapies adult vasculogenesis may arise
(Kocher et al., 2001; Smart et al., 2010), it is important
to carefully consider that this process does not appear to be
a major aspect of the normal adult healing response. A
second important insight is that in addition to recruiting
and remodeling pre-existing arterial interconnections, a
range of diverse but powerful factors contribute to
improving the vascular supply and vascular healing, includ-
ing immune function and the expression of numerous
angiogenic ligands and their receptors. It is critical that
the complexity of these vascular programs is not
underestimated because, as also demonstrated by the
failure of numerous angiogenic gene therapy studies over
the past 2 decades (Henry et al., 2007; Gupta et al., 2009),
the simple administration of a single gene or factor is
unlikely to promote clinically meaningful vascular regen-
eration. A third important point arising from these studies
of C57BL/6 versus BALB/c is that the same vascular
regenerative approach may not work in all individuals.
Indeed, whereas the mice described above differed only in
their genetic makeup, the clinical landscape of patients
requiring cardiovascular regenerative therapies contains
dramatic differences in genetics, co-morbidities, patient
age, extent of cardiac disease and the clinical disease
state (e.g. cardiomyopathy versus post-MI cardiac dys-
function). Thus, inter-patient variability in the response
to any specific regenerative therapy may be significant,
and a patient- and disease-specific approach may be
required.Human arteriogensis and angiogenesis
As in the mouse, the limited human data available strongly
support the paradigm that remodeling and adaptation of
pre-existing vascular interconnections (arteriogenesis) is the
primary mechanism responsible for providing a new vascular
supply in human cardiovascular disease states. Seminal studies
from the 1960’s were the first to demonstrate that coronary
collateral arterioles existing in the normal human heart can be
recruited to grow into larger structures to prevent myocardial
necrosis (Fulton, 1964). This work is supported by contemporary
studies (Zbinden et al., 2004, 2007), including the finding that
after a period of exercise training the heart is able to recruit
sufficient collateral vessels to avoid short term ischemia with
target vessel occlusion (Zbinden et al., 2007). In addition to
arteriogenesis, there is a wealth of data to support the
occurrence of angiogenesis in the adult, that is, the formation
of new capillaries from preexisting vessels by the sprouting or
splitting of preexisting vessels by transcapillary pillars or posts
of extracellular matrix and/or cells (Kovacic et al., 2008a). A
myriad of proteins and signaling pathways are involved in
angiogenesis and arteriogenesis, including HIF-1α, HGF, VEGF,
platelet-derived growth factor (PDGF), FGF, monocyte
chemoattractant protein (MCP-1), nitric oxide and many
more. While we do not propose to review this entire field,
interested readers are referred to the many excellent articles
on this topic (Kovacic et al., 2008a; Cochain et al., 2013). In
addition to angiogenesis and arteriogenesis, other mechanisms
of new vessel formation in the adult have been proposed such as
‘adult vasculogensis’ (de novo formation of new vessels from
progenitor cells) (Tepper et al., 2005), However, as discussed a
significant role for this process remains to be convincingly
shown in the normal healing response (Ziegelhoeffer et al.,
2004; Simons, 2005).
Therefore, what emerges in the adult human is a picture
similar to that in the mouse, where the additional demand for
increased blood supply and/or oxygenation is met by
the adaptation, remodeling and growth of preexisting
vascular structures. The available data indicate that de novo
appearance of new vessels where none existed previously, from
either progenitor or other cells, is not a commonly executed
adult biologic program (if it occurs at all). We believe that this
fact must be respected in cardiovascular regenerative medicine
strategies, as it suggests that therapeutic de novo vessel
formation will require a very sophisticated strategy, rather
than merely upregulating normal biologic programs. However,
while the above processes of new vessel formation in the adult
human are consistent with observations in mice, we are yet to
reconcile the fact that clinical revascularization studies have
shown that these smaller sized vessels created during the
normal repair process are inadequate to avoid the scenario of
myocardial hibernation. It remains to be seen if it will be
possible to augment these normal biologic programs such that
large vessels are generated.Cell therapy and new vessel formation – what
have we learned so far?
As readers of this article will be aware, a plethora of
cell-based cardiovascular regenerative studies have been
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cell therapy under evaluation or the experimental model,
many investigators have taken steps to evaluate the
potential vascularization effects of their specific therapy.
However, this has often been by fairly crude measures such
as counting the number of capillaries or endothelial cells.
Few studies have put significant efforts into adequately
defining the physiologic adequacy of any new vessel for-
mation. While we cannot review each study that has
examined vessel formation, we present here what we
perceive to be some of the learning points and messages
from these endeavors, which might inform our objective of
achieving functional vascularization in the context of
cardiac and cardiomyocyte regeneration.Early cell-therapy studies – bone marrow-derived
and circulating progenitor cells
In adult humans, it is an interesting historical note that the
first reported description of a putative progenitor endothe-
lial cell in 1997 (Asahara et al., 1997) predated what is
considered the first rigorous description of a resident adult
cardiac stem cell population by 6 years (Beltrami et al.,
2003). As a result, early efforts at cell-based regenerative
therapies focused on harnessing progenitor endothelial and
other ‘angiogenic’ cells to increase vascularity. In what was
a landmark paper at the time, in 2001 Itescu and co-workers
studied the intravenous administration of human CD34+ cells
into athymic nude rats following ligation of the left anterior
coronary artery (Kocher et al., 2001). It was reported that
this therapy led to de novo new blood vessel formation in the
infarct bed (i.e. adult vasculogenesis) and proliferation of
preexisting vasculature (angiogenesis), which contributed to
the salvage of viable myocardium (Kocher et al., 2001).
Remarkably, in the same year, it was also described that
bone marrow-derived progenitor cells could not only give
rise to new vessels, but also cardiomyocytes (Orlic et al.,
2001). These and other studies triggered a wave of
enthusiasm for the use of bone marrow derived and/or
circulating cell-based therapies aiming to augment vascu-
larity (and even generate cardiomyocytes). However, in the
ensuing years several critical lessons have been learned that
have somewhat dampened the initial enthusiasm for bone
marrow-derived or circulating angiogenic cells. Foremost
has been that the therapeutic translation of this approach
to humans has not been as spectacularly successful as
these early animal studies promised. Many groups,
ourselves among them (Kovacic et al., 2008b; Chih et al.,
2012), embarked on studies using bone marrow-derived cells,
circulating progenitor endothelial cells or ‘hemangioblasts’
aiming to improve vascularity. While animal studies using
these cells showed almost overwhelming efficacy, pivotal
clinical studies have often failed to deliver positive results.
Notably, three consecutive randomized studies conducted
under the banner of the US National Institutes of Health
(NIH)–sponsored Cardiovascular Cell Therapy Research
Network (CCTRN) recently reported negative findings
using various bone marrow-derived cell populations in
cardiovascular disease patients (Traverse et al., 2011,
2012; Perin et al., 2012). While clinical meta-analyses
have suggested small to modest effects (Delewi et al.,2013; Jeevanantham et al., 2012) and further phase III
human studies are ongoing (Sheridan, 2013), meaningful
improvements in clinical outcomes and even surrogate
measures remain to be convincingly demonstrated. Al-
though a possible exception may be bone-marrow derived
mesenchymal stem cell therapy (Heldman et al., 2014; Hare
et al., 2012), potential beneficial effects appear predom-
inantly due to paracrine signaling from the administered
cell population, which often fails to engraft and survive
beyond 1–2 weeks (Fang et al., 2011; Deuse et al., 2009).
While paracrine signaling might help hypoxic or metaboli-
cally challenged cardiomyocytes survive an acute insult, it
is difficult to conceptually envision how short-term para-
crine effects could help improve vascularization in the
long-term, especially when the clinical experience with
hibernating myocardium and revascularization suggests
that large, epicardial-like vessels are required for adequate
myocardial perfusion.Contemporary studies of bone marrow-derived cells
The above comments notwithstanding, it is encouraging that
several recent studies using bone marrow-derived cells have
shown promise, at least for the generation of small vessels.
While, as we have reviewed, this is suboptimal from a
clinical perspective and large, epicardial-like vessels should
remain the long-term goal of this field, these studies offer
hope for the future development of a more robust
cell-therapy derived vasculature.
Among these contemporary studies, Duran et al. (2013)
demonstrated that a novel c-kit+Sca-1+ “cortical bone-
derived stem cell” population improved survival and cardiac
function when injected into mice following MI. Salubrious
effects were greater than those seen with c-kit+Sca-1+
cardiac-derived stem cell (CSC) injection. Cortical bone-
derived stem cells engrafted and survived until at least
6 weeks after injection, and differentiated into mature
cardiac tissue, including endothelial cells, smooth muscle
cells and small-sized (arteriolar) vessels (Fig. 4). Cardiac-
derived stem cells did not show these effects. Though
somewhat surprising that control CSCs did not show an effect
(see section below on CSCs), this nonetheless remains an
encouraging finding. While yet to be harnessed to generate
larger coronary vessels, we expect c-kit+Sca-1+ cortical
bone-derived stem cells will receive heightened attention
in the coming years.
Serving as another example of incremental translation-
al gains being made with bone marrow-derived cells,
Houtgraaf et al. (2013) conducted a fairly large-scale
study of mesenchymal precursor cell administration via
the intracoronary route in a large animal (ovine) model of
MI. The question of durable cell engraftment versus
paracrine effects was not rigorously studied, but in
addition to various beneficial effects on left ventricular
ejection fraction and other cardiac indices, the investiga-
tors observed a N 50% increase in capillary density with
mesenchymal cell therapy. Perhaps more impressive,
arteriolar density in the infarct zone was doubled by
active cell therapy.
Despite these recent promising basic and translational
studies using bone marrow-derived cells and ongoing
Figure 4 Vascularization by cortical bone marrow-derived stem cells. Six weeks after MI and injection of enhanced green
fluorescent protein (EGFP)-marked cortical bone-derived c-kit+Sca-1+ stem cells, mice were harvested and evaluated for engraftment
and differentiation into cardiac and vascular cells. Shown here is staining for α-smooth muscle actin (αSMA; white), von Willebrand
Factor (vWF; red) and EGFP (green). Nuclei were labeled with 4’, 6-diamidino-2-phenylindole (DAPI; blue). Scale bars = 10 μm.
Reproduced with permission from Duran et al. (2013).
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achieve meaningful vascular formation in patients using
these cells. To this point, van der Laan et al. (2011)
recently published their findings in patients that received
either an intracoronary infusion of bone marrow mono-
nuclear cells (n = 23), peripheral blood mononuclear cells
(n = 18) or sham therapy (control; n = 19) following reperfused
ST-segment elevation MI. Evaluating microcirculatory flow in
the infarct-related artery measured invasively in the catheter-
ization laboratory by intracoronary Doppler flow wire at
4 months after MI, there was no difference between control
patients and those in either of the active treatment groups. As
the authors state, this data does not support the hypothesis of
enhanced neovascularization after this mode of cell therapy.
As a further cautionary note regarding these cells,
while paracrine and other effects may augment new vessel
formation, a series of well conducted studies have now
convincingly demonstrated that bone marrow-derived cells
do not make a direct contribution to the vascular endothe-
lium (Hagensen et al., 2010; Ohle et al., 2012; Purhonen et
al., 2008). These studies have investigated bone marrow cell
contributions to diverse biologic models (atherosclerosis,
tumor growth, hyperoxia-induced pulmonary injury, aging)using rigorous lineage tracking systems, and have dispelled
earlier notions of a bone marrow-derived cell contribution to
endothelial populations (Hagensen et al., 2010; Ohle et al.,
2012; Purhonen et al., 2008).The existence of a bipotent hemangioblast?
The putative but controversial (Kovacic and Boehm, 2009)
existence of a bipotent hemangioblast has been part of the
rationale for much of the abovementioned bone marrow
cell-based research. As a somewhat unexpected finding from
direct reprogramming and other related studies spawned
from the discovery of induced pluripotent stem cells, we
have recently moved somewhat closer to unravelling the
complex cellular biology that surrounds the origins of early
hematopoietic and endothelial cells. Specifically, we appear
to be slowly understanding that a truly bipotent hemangio-
blast is perhaps less likely to exist, or at least is less common
in the adult, than previously thought. Recent studies based
on cellular reprogramming and related lines of investigation
have independently shown that during progressive com-
mitment toward a hematopoietic cell fate, cells pass through a
Figure 5 Schematic illustration of reprogramming to hema-
topoietic stem cells. Reproduced from Pereira et al. (2013), with
permission from Elsevier. Abbreviations not previously defined:
HSC, hematopoietic stem cell; hu, human; LT-HSC, long-term-
hematopoietic stem cell.
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signature. In our studies of directly reprogramming murine
fibroblasts to hematopoietic stem cells, fibroblasts initially lose
their mesenchymal signature, then adopt a transitory
endothelial-like gene expression pattern, which is then pro-
gressively lost as the cells adopt a hematopoietic stem cell fate
(Fig. 5) (Pereira et al., 2013). Gene expression patterns were
not supportive of the existence of a bipotent hemangioblast
population. This finding has been corroborated by other groups.
For example, Rafii et al. (Rafii et al., 2013) demonstrated that
the hematopoietic derivatives of human embryonic stem cell
populations originate from endothelial cells via endothelial to
hematopoietic transition (a specialized type of epithelial to
mesenchymal transition). Further supporting evidence has also
been provided by in vivo experiments where it has been shown
that ‘hemogenic endothelial cells’ (rather than bipotent
hemangioblasts) undergo endothelial to hematopoietic transi-
tion to give rise to primitive hematopoietic cells (Zhen et al.,
2013). This shift in our understanding of the developmental
origins of endothelial and hematopoietic cells is another of the
many factors that need to be considered in the design of future
cell therapy studies aiming to improve vascularity. Moreover,
the fact that adult hemangioblasts may be a rare biologic entity
(if they exist at all) may help to explain the inconsistent results
that have arisen from many of the clinical studies conducted to
date which, at their core, were founded on adaptations of
hematopoietic transplant techniques to the generate new
vessels.
Can resident adult cardiac stem cells form physio-
logically significant new vessels?
Over a decade ago, the first formal characterization of
resident adult CSCs described that, in addition tocardiomyocytes, c-kit+ CSCs are capable of differentiating
into endothelial and smooth muscle cells, and forming
vascular structures (Beltrami et al., 2003). In an important
paper titled “Formation of large coronary arteries by cardiac
progenitor cells”, the same investigators later demonstrated
that rat c-kit+ CSCs could be activated ex vivo with
insulin-like growth factor-1 (IGF-1) and HGF, and then
injected into the MI border zone in a rodent model
(Tillmanns et al., 2008). These functionally enhanced CSCs
engrafted within the host myocardium, proliferated and
differentiated into endothelial cells, smooth muscle cells
and cardiomyocytes. Vascular lineage differentiation was
mediated by HIF-1α upregulation, which promoted stromal-
derived factor-1 (SDF-1) secretion from hypoxic coronary
vessels, with SDF-1 signaling being a key event in CSC
commitment to a vascular fate. As one of the few papers we
are aware of to demonstrate the formation of more
substantive vessels, these activated CSCs formed conductive
and intermediate-sized coronary arteries together with
capillaries and smaller vessels (Fig. 6) (Tillmanns et al.,
2008). These vessels were connected with the host coronary
circulation, and this increase in vascularization more than
doubled blood flow in the MI zone. This significant
vascularization effect involving formation of medium-sized
vessels, together with CSC-mediated myocardial regenera-
tion, attenuated postinfarction remodeling, reduced infarct
size and improved cardiac function (Tillmanns et al., 2008).
As somewhat of a follow-up study to the above,
18 months later the same group published a second paper
demonstrating the formation of larger sized vessels (Bearzi
et al., 2009). Rather than relying on ex vivo cytokine
stimulation of c-kit+ CSCs, on this occasion the approach
was to isolate a population of human heart-derived vascular
progenitor cells, defined by cells co-positive for c-kit and
VEGFR-2. These c-kit+VEGFR-2+ cells were found to occupy
vascular niches in the walls of coronary vessels, and in vitro
were self-renewing, clonogenic and able to differentiate
predominantly into endothelial and smooth muscle cells, but
also cardiomyocytes. In a canine myocardial ischemia model
that recapitulated the situation of hibernating myocardium,
injected c-kit+VEGFR-2+ cells were shown to regenerate
large, intermediate, and small human coronary arteries that
were connected to the host circulation. This regenerative
process included differentiation of the injected cells
into endothelial and smooth muscle cells (Fig. 7), and a
corresponding increase in coronary blood flow with func-
tional improvement of ischemic myocardium (Bearzi et al.,
2009). These two provocative and back-to-back papers from
the Anversa group are the first we are aware of that provide
evidence to suggest that a cell-based therapy could poten-
tially regenerate medium or even large caliber vessels that
have the potential to significantly augment coronary flow.
The latter of these two studies was also specific in
addressing the clinically relevant situation of hibernating
myocardium. Since this time others have also reported on
the likely existence of c-kit+ vascular progenitor cells that
reside in the adult heart. Indeed, it has been suggested that
in the adult c-kit+ CSCs do not support post-MI cardio-
myogenesis, but rather, are only able to form vascular
structures (Jesty et al., 2012). However, based on post-MI
large animal studies (Bolli et al., 2013) it would seem that
administration of c-kit + CSCs alone may be insufficient for
Figure 6 Large vessel formation by activated c-kit+ CSCs. Large vessel formation by c-kit+ CSCs activated ex vivo with IGF-1 and
HGF, and injected into the MI border zone in rats. (A) Epimyocardium of an infarcted heart at 2 weeks after cell administration: three
new coronary arteries (Upper, EGFP, green) are present in the spared myocardium (SM) and border zone (BZ). The arrow points to a
branching vessel. Colocalization of EGFP and αSMA is shown (Lower, orange). Preexisting coronary branches are EGFP-negative
(Upper) and αSMA-positive (Lower, red, asterisks). A cluster of EGFP positive cells is present at the injection site (IS). Myocytes, αSA:
white. (B) Large regenerated arteries (Upper, EGFP, green) in spared myocardium at 2 weeks. Colocalization of EGFP and αSMA is
shown (Lower, orange). Inset illustrates endothelial cells (vWF, white). Reproduced with permission from Tillmanns et al. (2008),
Copyright (2008) National Academy of Sciences, U.S.A.
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require other measures such as biologic stimulation (e.g. ex
vivo CSC stimulation using cytokines prior to administration)
(Tillmanns et al., 2008) or further cell purification (e.g. into
c-kit+VEGFR-2+ vascular progenitors) (Bearzi et al., 2009).
Nevertheless, we believe that these data regarding c-kit+
CSCs serve as important proof of principle for the possibility
of generating large vessels within the heart, and point the
way for future studies. Furthermore, there is additional
cause for excitement in the arena of resident vascular
progenitor cells within the heart, with the Chien laboratory
recently describing a population of endothelial progenitor
cells located in the outflow tract of fetal hearts, identified
by expression of Isl1 and VE-Cadherin (Lui et al., 2013).
These cells also express VEGF-A, VEGFR-1 and VEGFR-2, and
are highly responsive to VEGF stimulation. While their fate
and role in the adult remain to be defined, the identification
of these and other resident stem/progenitor cells within the
heart with vessel forming capacity (Chong et al., 2011)opens the door to further regenerative possibilities for
robust cardiac vascular formation.Epicardial-derived cells and vessel formation
There is certain intuitive appeal in investigating the
possibility that epicardial-derived cells might harbor vessel
forming capacity, because in the adult the large coronary
arteries (left anterior descending, circumflex, right coro-
nary) are epicardial structures. In 2007 Smart et al. (2007)
published a major paper suggesting that epicardial-derived
precursor cells could be stimulated to induce coronary
vasculogenesis and angiogenesis by treatment with thymosin
β4, an actin monomer binding protein. Mutant mice with
attenuated thymosin β4 signaling demonstrated impaired
smooth muscle differentiation and migration with defective
coronary vascular formation, while thymosin β4 treatment
was able to rejuvenate adult epicardial explants and trigger
Figure 7 Large vessel formation by activated cardiac c-kit+VEGFR-2+ cells. Generation of large coronary arteries by the injection of
EGFP-labeled c-kit+VEGFR-2+ cells into canine hearts with coronary stenosis. Arteries 0.9 and1.3 mm in diameter were detected. All
smooth muscle cells are positive for αSMA (red), EGFP (green), αSMA/EGFP (yellowish), and Alu probe (white; a probe marking
human-derived cells). Preexisting coronary vessels (arrows) are αSMA positive and EGFP and Alu probe negative. Reproduced with
permission from Bearzi et al. (2009).
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al., 2007). This group then went on to show that in control
mice subjected to MI there was an endogenous endothelial
response with formation of a capillary network, how-
ever, mice treated with thymosin β4 at the time of MI
showed more mature vessel formation that included smooth
muscle cell recruitment (Smart et al., 2010). These new
coronary vessels in thymosin β4-treated mice occupied an
expanded subepicardial space and the immediate underlying
myocardium, whereas neither expansion of the subepi-
cardium nor an associated vascular network were observed
in control hearts. Interestingly, the majority of smooth
muscle and endothelial cells involved in this thymosin
β4-stimulated vascular response were not derived from
canonical epicardial-derived precursor cells (Smart et al.,
2010). Nevertheless, compared to control mice undergoing
MI, thymosin β4-treated mice had a 1.2-fold increase in
number of perfused coronary vessels (smooth muscle-lined
arterioles) following 28 days of thymosin β4 treatment, a
3.5-fold increase in the number of endothelial cells after
only 4 days and a 2-fold increase in vessel area after 7 days
of thymosin β4 treatment post-MI (Smart et al., 2010).
Importantly, at the present time thymosin β4 treatment has
only been shown to induce the formation of arterioles and
the ability of this approach to generate medium or large
sized vessels is unknown. Furthermore, controversy has
arisen regarding the developmental importance of thymosin
β4 (Smart and Riley, 2013), with opposing data suggestingthat thymosin β4 plays a key role in vascular smooth muscle
cell recruitment to forming vessels and thus to vessel wall
stability (Rossdeutsch et al., 2012), while others have
argued that thymosin β4 plays no role whatsoever in vascular
development (Banerjee et al., 2012, 2013). Additional
research is required to clarify these issues and to explore
whether thymosin β4-based therapies can provide a more
robust arterial supply than has been demonstrated in the
studies conducted to date (Smart et al., 2007, 2010).
Another potential approach to harnessing epicardial cells
was recently revealed using VEGF-A stimulation. In a cell-free
approach, intramyocardial injection of synthetic modified
RNA (modRNA) encoding human VEGF-A resulted in the
mobilization of Wilms’ tumor 1 (WT1)-expressing epicardial
progenitor cells and redirection of their differentiation toward
endothelial cells and other cardiovascular cell types in a
mouseMImodel (Zangi et al., 2013).While a formal evaluation
is yet to be performed of the size and quality of new vessel
formation that arises from VEGF-A modRNA therapy, it is
notable that this therapy improved heart function and
enhanced long-term survival (Zangi et al., 2013).
Investigation of the potential of epicardial-directed
therapies for cardiac regeneration and vessel formation is
in its infancy. However, these studies appear to hint at the
potential for a major, albeit latent vessel forming capacity
of epicardial cells and/or epicardial-directed therapies. As
previously mentioned this approach has intuitive appeal as
this is the location of the large arteries of the heart. We
678 K.C. Michelis et al.anticipate much focus on the epicardium and its capacity for
vascular formation going forwards.Skeletal myoblast therapy
Perhaps somewhat surprisingly, investigators are continuing to
pursue the potential beneficial effects of skeletal myoblast
therapy, yielding remarkably informative results. Importantly,
injected skeletal myoblasts do not couple to or therefore
contract in synchrony with native cardiomyocytes (Leobon et
al., 2003), and a phase II randomized placebo-controlled clinical
trial failed to show efficacy (Menasche et al., 2008). Neverthe-
less, the rationale for this study was that skeletal myoblasts
likely have superior survival compared to other cell populations
(as described above) in a post-MImodel, and that they therefore
may be used to explore new vessel formation in the context of
cellular grafts. Using a rodent MI model with skeletal myoblasts
administered directly into the infarct zone at the time of
coronary artery ligation, Weyers et al found that skeletal
myoblast grafts developed an extensive vascular network
(Weyers et al., 2013). Micro computed tomographic imaging of
vessels larger than 25 μm diameter revealed that vascular
structures extended throughout the graft regions, including
large and small vessels, and both arteries and veins. Quantifi-
cation of the extent of branching of the left coronary artery
(which was the ligated vessel) revealed that myoblast therapy
induced a significant increase in the number ofmajor secondary
and tertiary arterial branches. Important limitations of this
work were that neither the molecular mechanisms of vessel
formation nor the cellular origins (host versus donor) were
explored, and a great deal remains to be done in this line of
research. However, despite the fact that this therapy has been
almost abandoned in clinical studies, it appears reasonable to
use skeletal myoblast therapy as a model of cellular engraft-
ment to understand the processes facilitating the formation and
inter-connection of large perfusing coronary vessels.Cardiac development, embryonic and induced
pluripotent stem cells
The discovery of induced pluripotent stem cells by Shinya
Yamanaka was a milestone in cellular biology that had a
profound impact on the direction of cardiovascular stem cell
research. Prior to this, investigators working with embryonic
stem cells were already engaged in the task of driving
pluripotent cells toward differentiated cardiovascular cell
fates. As reviewed in this issue of Stem Cell Research, these
differentiation programs are intimately related to embryon-
ic cardiovascular developmental pathways.Developmental origins of the coronary vasculature
The developmental origins of the coronary circulation have
been extensively reviewed elsewhere (Kovacic et al., 2012)
and are beyond the scope of this article. However, there are
several key principles of cardiac vascular development that are
of relevance to our review, particularly in the context of cell
reprograming, induced pluripotent and embryonic stem cells.Foremost is the fact that bi- or multi-potent progenitor cells
are strongly implicated in cardiac vascular formation.
Multipotent cardiovascular progenitor cells are specified
from early mesoderm and several studies have suggested
that bi- or multipotent progenitor cells are responsible for
both cardiomyocyte and cardiac vascular development.
For example, Kattman et al. (2006) suggested that a multi-
potent VEGFR-2-expressing cell, identified in head-fold
stage embryos, gives rise to cardiomyocytes, endothelial
and smooth muscle cells. On the other hand, Wu et al. (2006)
suggested that Nkx2.5-expressing bipotent cells may give
rise to cardiomyocytes and smooth muscle cells, while
Moretti et al. (2006) provided data to indicate that a
multipotent islet-1-expressing cell gives rise to cardio-
myocytes, endothelial and smooth muscle cells derived
from the second heart field. Later in development, while
there may be species-specific differences that remain to be
fully reconciled (Kovacic et al., 2012), it is likely that that
the coronary vessels derive additional contributions from
epicardial derived progenitor cells which, depending on
the specific species, appear potent for the formation
of endothelial cells, vascular smooth muscle cells, and
pericytes (see review) (Kovacic et al., 2012). Alternatively,
in mice at least, cardiac endothelial cells may derive from
the sinus venosus (Red-Horse et al., 2010).
While many more studies have addressed cardiac vascular
origins, the above summary indicates that, according to
Nature’s blueprint, cardiac vascular formation likely arises
in parallel with cardiomyocyte specification with a signifi-
cant contribution from common multipotent progenitor
cells. Indeed, this is underscored by the fact that we are
unaware of any genetically manipulated mice with signifi-
cant cardiac vascular defects that do not also manifest
perturbed gross heart development. We believe that the
dependency of cardiac vascular formation on multipotent
cardiac progenitor cells is an important developmental
program that must be respected in efforts with contempo-
rary cell-based regenerative therapies. For example and as
we explore further below, although there may be appeal in
restricting delivered cell therapies to a differentiated
cardiomyocyte fate to minimize the risk of teratoma and
tumor formation, it must be understood that differentiated
cardiomyocytes lack the primary capacity to generate
vessels.Perspectives on current reprogramming and
differentiation approachesAs readers will be aware, enormous efforts are now being
made in directing pluripotent and other cells toward cardio-
vascular cell fates. Recently, this research has begun to
focus on the prospects for direct in situ differentiation of
resident fibroblasts toward differentiated cell fates, and
cardiomyocytes in particular (Song et al., 2012; Qian et al.,
2012). While incredibly promising, a critical element lacking
in this approach of direct differentiation to cardiomyocytes
is that of vascularization. By definition, the application
of specific reprogramming factors selected to trigger the
reprogramming of fibroblasts to a cardiomyocyte fate, while
potentially effective at creating new cardiomyocytes and
679The cardiac stem cell compartmentmyocardium, ignores the need for vascular formation and
perfusion. Even though newly formed cardiomyocytes may
be able to stimulate modest capillary ingrowth, as we have
shown here by numerous examples this is almost certain to
be inadequate for proper cardiomyocyte functioning and
instead, would seem destined to create a situation of
hibernating myocardium involving the newly reprogrammed
cardiomyocytes. The same concerns can be raised for the
application of embryonic stem cell-derived cardiomyocytes,
or any therapy that primarily aims to replenish cardio-
myocytes without attention to vascular formation. As a case
in point, when human embryonic stem cell-derived cardio-
myocytes were very recently delivered into the infarcted
heart of non-human primates, it has been presented that the
grafts were perfused by a “sluggish vascular plexus” and that
“developing a brisk arterial supply is a substantial remaining
hurdle.” (Christoffels and Pu, 2013) While progress has also
been made in reprogramming toward vascular cell fates
(Pereira et al., 2013; Xiong et al., 2013; Ginsberg et al.,
2012; Margariti et al., 2012), much work remains to be done
before this approach can be expected to deliver robust
vascular formation.
While these early efforts remain encouraging, looking
ahead we foresee that the developmental paradigm of
multipotent stem cells being responsible for embryonic
cardiac formation will increasingly influence this field.
Although it is appropriate that initial efforts focus on
differentiation or reprogramming to only a single cell fate
(e.g. cardiomyocyte, endothelial), as we contend through-
out this article we believe that robust cardiac repair will
require broader regeneration of both cardiomyocytes and a
perfusing vasculature. It is plausible that the embryonic and
induced pluripotent stem cell fields will be critical in this
regard, as they hold the potential to permit differentiation
or reprogramming to multiple concurrent cardiovascular cell
fates. Despite the considerable technical obstacles that
need to be overcome, we envision several possible ways
in which this field may evolve. For example, a potential
area for research would be to develop differentiation and
reprogramming protocols to generate multipotent cardio-
vascular progenitor cells with restricted differentiation
abilities toward only cardiomyocytes, smooth muscle and
endothelial cells. This would limit tumor forming potential,
while providing the cellular substrate for comprehensive
cardiac repair. Another possible line of investigation
would be to develop in situ reprogramming protocols that
redirected fibroblasts toward all 3 differentiated cardio-
vascular cell types (cardiomyocytes, smooth muscle and
endothelial cells). Certainly, these and other exciting
prospects would appear cause for cautious optimism in this
still nascent area of investigation.Conclusions
At least five decades of experience presently informs clinical
practice for CAD and cardiac revascularization strategies.
While there is much that can be learned from this and
translated to our pursuit of cell-based regenerative ap-
proaches, perhaps the most obvious message is that a
suboptimal vascular supply leads to hibernating or ischemic
myocardium and poor clinical outcomes. At the presenttime, although our understanding of the salient cellular and
molecular processes is growing rapidly, the requirement of
providing an adequate and interconnected vasculature in
the context of cardiac regenerative therapy remains a
significant obstacle yet to be overcome. Nevertheless, as
we have reviewed, data is beginning to accumulate that is
shaping a platform of knowledge to propel this field forward.
While rudimentary, a degree of early success has been seen
for the generation of capillaries and at least small vessels
using various cell-based approaches. Other emerging fields
not reviewed here, such as tissue engineering and the
possibility of engineered vascular grafts, may also come into
play in the future. Therefore, while wemay be only beginning
to appreciate the importance of an adequate vasculature for
cardiac regeneration, at least some of the tools required to
work toward this objective may already be within our grasp.
While readers of this Stem Cell Research review series will be
tantalized by many new and stimulating research ideas,
we offer the simple but critical axiom that due attention
to concurrent vascularization will be required if we are
to succeed in our collective, long-term goal of achieving
meaningful cardiomyocyte and cardiac regeneration.Acknowledgments
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